A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers ...

A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Researchers have developed a new class of antibodies that amplify the immune system’s ability to fight cancer. By clustering ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...